Decoding HCAR3 Ligand Recognition: Structural Insights from Cryo-EM

Study Background and Research Question

The hydroxycarboxylic acid receptors HCAR2 (GPR109A/HM74A) and HCAR3 (GPR109B) are central to lipid metabolism regulation and are established targets for hypolipidemic agent development. While HCAR2 agonists are clinically relevant for dyslipidemia, their use is limited by adverse effects such as cutaneous flushing. In contrast, HCAR3 activation lacks these side effects, yet the molecular basis for its ligand recognition and selectivity remained obscure. Addressing this gap, Ye et al. (2025) set out to elucidate the structural determinants that govern agonist selectivity in HCAR3, aiming to inform the rational design of metabolic disorder research compounds with improved specificity and safety (Ye et al., 2025).

Key Innovation from the Reference Study

The reference study's core innovation lies in resolving the cryo-electron microscopy (cryo-EM) structures of HCAR3 in complex with various selective agonists, including compound 6O, D-phenyllactic acid, IBC293, and most notably, (R)-5-methyl-4-oxo-5-phenyl-4,5-dihydrofuran-2-carboxylic acid (Acifran). The authors also determined the structure of HCAR2 bound to Acifran, enabling direct comparison. These high-resolution structures (3.05–3.31 Å for HCAR3 complexes; 2.72 Å for HCAR2-Acifran) reveal, for the first time, the molecular interactions and binding pocket characteristics underlying HCAR3 ligand selectivity. This structural framework is crucial for guiding the development of targeted hypolipidemic agents with minimized off-target effects (Ye et al., 2025).

Methods and Experimental Design Insights

To dissect the basis of ligand recognition, the research team expressed HCAR3-Gi and HCAR2-Gi protein complexes in Sf9 cells, subsequently purifying the receptor-agonist assemblies. Cryo-EM data were collected for HCAR3 in complex with each agonist, as well as for the HCAR2-Acifran complex. The resulting three-dimensional density maps were deposited in the Electron Microscopy Data Bank (e.g., EMD-61573 for the Acifran-HCAR3 complex), with corresponding atomic coordinates available in the Protein Data Bank (e.g., 9JKX for Acifran-HCAR3).

Complementary functional assays were performed using HEK-293 cells to measure cAMP responses and validate ligand activity and selectivity. The integration of structural and pharmacological data allowed the team to attribute specific receptor-ligand interactions to differential agonist affinities and selectivities.

Core Findings and Why They Matter

The study elucidates several key structural determinants of HCAR3 ligand recognition:

• Binding Pocket Architecture: The orthosteric binding site of HCAR3 contains two sub-regions (R1 and R2). Compound 6O exhibited the highest affinity due to full occupation of both regions, whereas Acifran and other agonists showed distinct binding modes.
• Residue-Specific Selectivity: Differences at positions V/L832.60, Y/N862.63, and S/W9123.48 between HCAR3 and HCAR2, along with a π–π stacking interaction involving F1073.32 in HCAR3 (contrasting L1073.32 in HCAR2), underpin the selectivity of certain ligands for HCAR3. These features explain why some hypolipidemic agents modulate lipid signaling pathways more selectively (Ye et al., 2025).
• Implications for Drug Design: The structural insights enable rational design of HCAR3-specific agonists to avoid HCAR2-mediated side effects, such as flushing, thus supporting safer lipid metabolism research and translational drug development.

By clarifying the molecular determinants of selectivity, this research provides a blueprint for engineering next-generation metabolic disorder research compounds and optimizing hypolipidemic agents for experimental and clinical use.

Comparison with Existing Internal Articles

The findings of Ye et al. (2025) directly inform several recent analyses of selective hydroxycarboxylic acid receptor agonists. For example, a prior article (Acifran: Selective HM74A/GPR109A Agonist for Lipid Metabo...) summarized Acifran as a benchmark HM74A/GPR109A and GPR109B agonist, highlighting its role in lipid metabolism regulation studies. The new cryo-EM structures now provide the molecular rationale for Acifran’s high selectivity and robust performance in lipid signaling pathway modulation. Additionally, the article Structural Insights into HCAR3 Agonist Selectivity via Cryo-EM contextualizes how these atomic-level details can inform the rational design of hypolipidemic agents with improved selectivity and reduced off-target effects, echoing the present study’s practical implications.

Moreover, workflow-oriented resources (Acifran in Lipid Metabolism Research: Protocols & Innovations) describe how Acifran enables precise dissection of HCAR signaling in the laboratory. The structural breakthroughs reported by Ye et al. (2025) now provide a mechanistic foundation for these protocols, supporting robust experimental design in metabolic disorder research.

Limitations and Transferability

While the reported structures offer unprecedented resolution of the HCAR3 and HCAR2 ligand-binding landscapes, there are several limitations:

• The study employed Sf9 insect cells for receptor expression, which, while effective for structural studies, may not fully recapitulate post-translational modifications present in mammalian systems.
• Although cAMP assays in HEK-293 cells confirmed ligand activity, additional functional studies in primary human cells or animal models would be required to validate translational relevance.
• The observed ligand selectivity is based on a limited set of structurally characterized agonists; further exploration of diverse chemical scaffolds will be necessary to generalize the findings.

Nonetheless, these high-resolution datasets serve as a critical starting point for structure-based drug design and for advancing lipid metabolism research using small-molecule agonists with defined selectivity profiles.

Protocol Parameters

• Receptor-ligand complex formation: Express HCAR3-Gi or HCAR2-Gi complexes in Sf9 cells; purify using affinity chromatography prior to cryo-EM sample preparation (Ye et al., 2025).
• Agonist concentration for binding studies: Use concentrations close to previously published EC₅₀ values for Acifran and related compounds (consult product information for solubility and handling).
• cAMP functional assay: HEK-293 cells are suitable for measuring receptor activity; optimize agonist exposure times and concentrations based on desired assay sensitivity.
• Structural characterization: Cryo-EM grids should be prepared with purified receptor-agonist complexes at concentrations supporting optimal particle distribution (as performed in the reference study).
• Storage and stability: For Acifran, store stock solutions at -20°C and use freshly prepared solutions for each experiment to maintain compound integrity (product information).

Research Support Resources

Researchers aiming to replicate or extend the structural and functional analyses of HCAR3 agonist selectivity can utilize Acifran (SKU B6848), a well-characterized selective agonist for HM74A/GPR109A and GPR109B. This compound supports detailed interrogation of lipid metabolism and signaling pathway modulation in both structural and cellular assay contexts. For optimal results, reference the product dossier for stability and solubility guidance. Additional methodological details and protocol refinements are available in the cited internal articles, which provide workflow strategies and troubleshooting insights for metabolic disorder research.